1000% disagree. He should be aligned with our interests, not the toxics SPV. If his shares were awarded in SPV next year, he would be in clear fiducial caution zone as he would be incentivized to have a low share price for his own conversion. By converting now, which he deserves approximately given he worked for 2.5 years at this approximate price to make all this happen, he is not incentivized to limit further dilution, push for upside from here, and allows management to maintain some respectable controlling interest in the company.
(1)
(1)
Amarantus Bioscience Holdings (AMBS) Stock Research Links